These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1377314)

  • 21. [Affection of aprotinin on tissue factor pathway inhibitor in peri-operation of cardiac direct vision operation].
    Chen S; Li G; Xu L; He Z
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):26-8. PubMed ID: 11938732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply to invited letter concerning: Aprotinin (J Thorac Cardiovasc Surg 1991; 101:1103-4).
    Blauhut B; Lundsgaard-Hansen P
    J Thorac Cardiovasc Surg; 1992 Feb; 103(2):386-7. PubMed ID: 1370972
    [No Abstract]   [Full Text] [Related]  

  • 23. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
    Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
    Wendel HP; Heller W; Gallimore MJ
    Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of systemic anticoagulation during cardiopulmonary bypass.
    Bidstrup BP
    Ann Thorac Surg; 1996 Mar; 61(3):781-2. PubMed ID: 8619692
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.
    van Oeveren W; Harder MP; Roozendaal KJ; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 May; 99(5):788-96; discussion 796-7. PubMed ID: 1691806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low heparinization and heparin-bonded circuits.
    Hill RC
    Ann Thorac Surg; 1997 Oct; 64(4):1221-2. PubMed ID: 9354574
    [No Abstract]   [Full Text] [Related]  

  • 32. Intraoperative coronary thrombosis: can aprotinin and protamine be incriminated?
    Umbrain V; Christiaens F; Camu F
    J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):198-201. PubMed ID: 7515707
    [No Abstract]   [Full Text] [Related]  

  • 33. Heparin resistance after intraoperative platelet-rich plasma harvesting.
    Wickey GS; Keifer JC; Larach DR; Diaz MR; Williams DR
    J Thorac Cardiovasc Surg; 1992 Jun; 103(6):1172-6. PubMed ID: 1597982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary on: The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald D
    Perfusion; 2009 Mar; 24(2):97. PubMed ID: 19654151
    [No Abstract]   [Full Text] [Related]  

  • 36. Urban myths and the ACT: what is not true and what really matters when it comes to monitoring anticoagulation.
    Searles B
    J Extra Corpor Technol; 2006 Mar; 38(1):56-8. PubMed ID: 16637527
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effects of aprotinin on activated coagulation time in the patients during cardiopulmonary bypass].
    Xu L; He Z; Shen J
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):215-6. PubMed ID: 10681854
    [No Abstract]   [Full Text] [Related]  

  • 38. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heparin management by activated coagulation time during cardiopulmonary bypass].
    Shikano K; Shinpo H; Nasu M; Morimoto T; Suzuki T; Yada I; Kusagawa M
    Kyobu Geka; 1981; 34(12):934-7. PubMed ID: 7349352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.